Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 428

1.

A specific proteinase 3 activity footprint in α1-antitrypsin deficiency.

Newby PR, Crossley D, Crisford H, Stockley JA, Mumford RA, Carter RI, Bolton CE, Hopkinson NS, Mahadeva R, Steiner MC, Wilkinson TMA, Sapey E, Stockley RA.

ERJ Open Res. 2019 Aug 5;5(3). pii: 00095-2019. doi: 10.1183/23120541.00095-2019. eCollection 2019 Jul.

2.

Neutrophil phenotypes in chronic lung disease.

Hughes MJ, Sapey E, Stockley R.

Expert Rev Respir Med. 2019 Aug 21:1-17. doi: 10.1080/17476348.2019.1654377. [Epub ahead of print]

PMID:
31394045
3.

Quality of life in adults with muscular dystrophy.

Jacques MF, Stockley RC, Onambele-Pearson GL, Reeves ND, Stebbings GK, Dawson EA, Groves L, Morse CI.

Health Qual Life Outcomes. 2019 Jul 15;17(1):121. doi: 10.1186/s12955-019-1177-y.

4.

Model-based evaluation of the long-term cost-effectiveness of systematic case-finding for COPD in primary care.

Lambe T, Adab P, Jordan RE, Sitch A, Enocson A, Jolly K, Marsh J, Riley R, Miller M, Cooper BG, Turner AM, Ayres JG, Stockley R, Greenfield S, Siebert S, Daley A, Cheng KK, Fitzmaurice D, Jowett S.

Thorax. 2019 Aug;74(8):730-739. doi: 10.1136/thoraxjnl-2018-212148. Epub 2019 Jul 8.

5.

PULSE-I - Is rePetitive Upper Limb SEnsory stimulation early after stroke feasible and acceptable? A stratified single-blinded randomised controlled feasibility study.

Chatterjee K, Stockley RC, Lane S, Watkins C, Cottrell K, Ankers B, Davies S, Morris MF, Fallon N, Nurmikko T.

Trials. 2019 Jul 1;20(1):388. doi: 10.1186/s13063-019-3428-y.

6.

Alpha-1 Antitrypsin Deficiency: A Predisposing Factor for the Development of Pulmonary Langerhans Cell Histiocytosis.

Ellis PR, Campbell EJ, Turner AM, Stockley RA.

Chronic Obstr Pulm Dis. 2019 Jul 24;6(3):206-209. doi: 10.15326/jcopdf.6.3.2019.0129. No abstract available.

7.

Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease?

Crossley D, Stockley R, Sapey E.

Drugs Aging. 2019 Jun 10. doi: 10.1007/s40266-019-00684-7. [Epub ahead of print] Review.

PMID:
31179525
8.

Corporate Memory and Rediscovering the Wheel.

Stockley RA.

Am J Respir Crit Care Med. 2019 Jul 1;200(1):2-4. doi: 10.1164/rccm.201901-0066ED. No abstract available.

9.

Getting stuck or choosing to stay? Neutrophil transit times in the lung in acute inflammation and COPD.

Sapey E, Stockley RA.

Thorax. 2019 Jul;74(7):631-632. doi: 10.1136/thoraxjnl-2018-213000. Epub 2019 May 16. No abstract available.

10.

The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial.

Campos MA, Geraghty P, Holt G, Mendes E, Newby PR, Ma S, Luna-Diaz LV, Turino GM, Stockley RA.

Am J Respir Crit Care Med. 2019 Aug 1;200(3):318-326. doi: 10.1164/rccm.201901-0010OC.

11.

Reply to Pouwels et al.: Confounding Factors Affecting sRAGE as a Biomarker for Chronic Obstructive Pulmonary Disease.

Stockley RA, Halpin D, Celli BR, Singh D.

Am J Respir Crit Care Med. 2019 Jul 1;200(1):114-115. doi: 10.1164/rccm.201903-0573LE. No abstract available.

12.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C.

Eur Respir J. 2019 May 18;53(5). pii: 1900164. doi: 10.1183/13993003.00164-2019. Print 2019 May. Review.

PMID:
30846476
13.

The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency.

Miravitlles M, Chorostowska-Wynimko J, Ferrarotti I, McElvaney NG, O'Hara K, Stolk J, Stockley RA, Turner A, Wilkens M, Greulich T; EARCO Clinical Research Collaboration; Members of the EARCO Clinical Research Collaboration.

Eur Respir J. 2019 Feb 14;53(2). pii: 1900138. doi: 10.1183/13993003.00138-2019. Print 2019 Feb. No abstract available.

PMID:
30765486
14.

Frequency of reported pain in adult males with muscular dystrophy.

Jacques MF, Stockley RC, Bostock EI, Smith J, DeGoede CG, Morse CI.

PLoS One. 2019 Feb 14;14(2):e0212437. doi: 10.1371/journal.pone.0212437. eCollection 2019.

15.

Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation.

Stockley RA, Halpin DMG, Celli BR, Singh D.

Am J Respir Crit Care Med. 2019 May 15;199(10):1195-1204. doi: 10.1164/rccm.201810-1860SO.

PMID:
30592902
16.

Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee.

Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, Fabbri LM, Frith P, Halpin DMG, Han M, Montes de Oca M, Nishimura M, O'Donnell D, Papi A, Pavord I, Roche N, Rodriguez-Roisin R, Salvi S, Singh D, Sin DD, Stockley R, López Varela MV, Vestbo J, Vogelmeier CF, Washko G, Wedzicha JA, Celli BR.

Ann Am Thorac Soc. 2019 Jan;16(1):29-39. doi: 10.1513/AnnalsATS.201808-557PS. No abstract available.

PMID:
30427736
17.

Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases.

Crisford H, Sapey E, Stockley RA.

Respir Res. 2018 Sep 20;19(1):180. doi: 10.1186/s12931-018-0883-z. Review.

18.

Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?

Stockley RA, Edgar RG, Starkey S, Turner AM.

Respir Res. 2018 Jul 20;19(1):137. doi: 10.1186/s12931-018-0844-6.

19.

Pharmacological treatment of COPD: the devil is always in the detail.

Singh D, Barnes PJ, Stockley R, Lopez Valera MV, Vogelmeier C, Agusti A.

Eur Respir J. 2018 Apr 19;51(4). pii: 1800263. doi: 10.1183/13993003.00263-2018. Print 2018 Apr. No abstract available.

PMID:
29674480
20.

ICS Use May Modify FEV1 Decline in α1-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils.

Low EV, Hughes SM, Zaffarullah S, Kantas D, Stockley RA, Turner AM.

Respiration. 2018;95(2):114-121. doi: 10.1159/000481867. Epub 2017 Dec 18.

21.

European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency.

Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, McElvaney NG, Parr D, Piitulainen E, Roche N, Stolk J, Thabut G, Turner A, Vogelmeier C, Stockley RA.

Eur Respir J. 2017 Nov 30;50(5). pii: 1700610. doi: 10.1183/13993003.00610-2017. Print 2017 Nov. Review.

22.

COPD10: Birmingham,United Kingdom, July 2016.

Stockley RA.

Chronic Obstr Pulm Dis. 2017 Jul 15;4(3):225-246. doi: 10.15326/jcopdf.4.3.2017.0137. No abstract available.

23.

Small airways disease: time for a revisit?

Stockley JA, Cooper BG, Stockley RA, Sapey E.

Int J Chron Obstruct Pulmon Dis. 2017 Aug 7;12:2343-2353. doi: 10.2147/COPD.S138540. eCollection 2017. Review.

24.

Erratum to "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary" [Arch Bronconeumol. 2017;53:128-49].

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DMG, Varela MVL, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Jul;53(7):411-412. doi: 10.1016/j.arbres.2017.06.001. English, Spanish. No abstract available.

25.

Is periodontitis a comorbidity of COPD or can associations be explained by shared risk factors/behaviors?

Hobbins S, Chapple IL, Sapey E, Stockley RA.

Int J Chron Obstruct Pulmon Dis. 2017 May 4;12:1339-1349. doi: 10.2147/COPD.S127802. eCollection 2017. Review.

26.

The Use of Plasmapheresis in Patients with Bronchiectasis with Pseudomonas aeruginosa Infection and Inhibitory Antibodies.

Wells TJ, Davison J, Sheehan E, Kanagasundaram S, Spickett G, MacLennan CA, Stockley RA, Cunningham AF, Henderson IR, De Soyza A.

Am J Respir Crit Care Med. 2017 Apr 1;195(7):955-958. doi: 10.1164/rccm.201603-0599LE. No abstract available.

PMID:
28362198
27.

Post Hoc: Two (or More) for the Price of One.

Stockley RA.

Am J Respir Crit Care Med. 2017 Apr 1;195(7):844-846. doi: 10.1164/rccm.201610-2132ED. No abstract available.

PMID:
28362196
28.

Maximal mid-expiratory flow detects early lung disease in α1-antitrypsin deficiency.

Stockley JA, Ismail AM, Hughes SM, Edgar R, Stockley RA, Sapey E.

Eur Respir J. 2017 Mar 29;49(3). pii: 1602055. doi: 10.1183/13993003.02055-2016. Print 2017 Mar.

29.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Mar;53(3):128-149. doi: 10.1016/j.arbres.2017.02.001. Epub 2017 Mar 6. English, Spanish. Erratum in: Arch Bronconeumol. 2017 Jul;53(7):411-412.

30.

A Mixed Methods Small Pilot Study to Describe the Effects of Upper Limb Training Using a Virtual Reality Gaming System in People with Chronic Stroke.

Stockley RC, O'Connor DA, Smith P, Moss S, Allsop L, Edge W.

Rehabil Res Pract. 2017;2017:9569178. doi: 10.1155/2017/9569178. Epub 2017 Jan 18.

31.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Eur Respir J. 2017 Mar 6;49(3). pii: 1700214. doi: 10.1183/13993003.00214-2017. Print 2017 Mar. Erratum in: Eur Respir J. 2017 Jun 22;49(6):.

32.

Patterns and characterization of COPD exacerbations using real-time data collection.

Ejiofor SI, Stolk J, Fernandez P, Stockley RA.

Int J Chron Obstruct Pulmon Dis. 2017 Jan 25;12:427-434. doi: 10.2147/COPD.S126158. eCollection 2017.

33.

Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Respirology. 2017 Apr;22(3):575-601. doi: 10.1111/resp.13012. Epub 2017 Mar 7.

34.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582. doi: 10.1164/rccm.201701-0218PP.

36.

Quantitative analysis of protease recognition by inhibitors in plasma using microscale thermophoresis.

Dau T, Edeleva EV, Seidel SA, Stockley RA, Braun D, Jenne DE.

Sci Rep. 2016 Oct 14;6:35413. doi: 10.1038/srep35413.

37.

Alpha-1 Antitrypsin Deficiency: Phenotypes and Quality of Life.

Stockley RA.

Ann Am Thorac Soc. 2016 Aug;13 Suppl 4:S332-5. doi: 10.1513/AnnalsATS.201507-436KV. Review.

PMID:
27564669
38.

Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?

Stockley RA, Edgar RG, Pillai A, Turner AM.

Int J Chron Obstruct Pulmon Dis. 2016 Aug 1;11:1745-56. doi: 10.2147/COPD.S111508. eCollection 2016.

39.

Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trial.

Jordan RE, Adab P, Sitch A, Enocson A, Blissett D, Jowett S, Marsh J, Riley RD, Miller MR, Cooper BG, Turner AM, Jolly K, Ayres JG, Haroon S, Stockley R, Greenfield S, Siebert S, Daley AJ, Cheng KK, Fitzmaurice D.

Lancet Respir Med. 2016 Sep;4(9):720-730. doi: 10.1016/S2213-2600(16)30149-7. Epub 2016 Jul 19.

PMID:
27444687
40.

Cohort Profile: The Birmingham Chronic Obstructive Pulmonary Disease (COPD) Cohort Study.

Adab P, Fitzmaurice DA, Dickens AP, Ayres JG, Buni H, Cooper BG, Daley AJ, Enocson A, Greenfield S, Jolly K, Jowett S, Kalirai K, Marsh JL, Miller MR, Riley RD, Siebert WS, Stockley RA, Turner AM, Cheng KK, Jordan RE.

Int J Epidemiol. 2017 Feb 1;46(1):23. doi: 10.1093/ije/dyv350. No abstract available.

PMID:
27378796
41.

COPD service delivery in the UK.

Stockley RA.

Lancet Respir Med. 2016 Jun;4(6):426-8. doi: 10.1016/S2213-2600(16)30082-0. Epub 2016 May 13. Review. No abstract available.

PMID:
27185521
42.

Pulmonary Physiology of Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, and Alpha-1 Antitrypsin Deficiency.

Stockley JA, Stockley RA.

Ann Am Thorac Soc. 2016 Apr;13 Suppl 2:S118-22. doi: 10.1513/AnnalsATS.201504-224KV.

PMID:
27115945
43.

Collaborative goal setting with adults attending physiotherapy at a specialist neuromuscular centre: is it always appropriate? A cross-sectional survey.

Hartley SE, Stockley RC.

Physiotherapy. 2016 Dec;102(4):320-326. doi: 10.1016/j.physio.2015.10.014. Epub 2015 Dec 2.

PMID:
27091330
44.

Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency and usual COPD.

Hampson JA, Stockley RA, Turner AM.

Respir Res. 2016 Mar 31;17:34. doi: 10.1186/s12931-016-0348-1.

45.

Lung density associates with survival in alpha 1 antitrypsin deficient patients.

Green CE, Parr DG, Edgar RG, Stockley RA, Turner AM.

Respir Med. 2016 Mar;112:81-7. doi: 10.1016/j.rmed.2016.01.007. Epub 2016 Jan 22.

46.

Pathophysiology of Emphysema and Implications.

Goldklang M, Stockley R.

Chronic Obstr Pulm Dis. 2016 Jan 15;3(1):454-458. doi: 10.15326/jcopdf.3.1.2015.0175.

48.

Lung Transplantation in Alpha-1-Antitrypsin Deficiency.

Stone HM, Edgar RG, Thompson RD, Stockley RA.

COPD. 2016;13(2):146-52. doi: 10.3109/15412555.2015.1048850. Epub 2015 Oct 21.

PMID:
26488418
49.

A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.

De Soyza A, Pavord I, Elborn JS, Smith D, Wray H, Puu M, Larsson B, Stockley R.

Eur Respir J. 2015 Oct;46(4):1021-32. doi: 10.1183/13993003.00148-2015. Epub 2015 Sep 4.

50.

Supplemental Content

Loading ...
Support Center